Immunotherapy has a major and expanding role in the treatment of cancer, including advanced prostate cancer. Over time there have been a number of naysayers as the immunotherapy Provenge has played the role whipping boy by critics. The common criticism leveled at Provenge can be summed up simply, “It doesn’t work.” The plain truth is [...]
One of the more difficult problems faced by some men treated with surgery as their primary treatment modality is post-prostatectomy incontinence (PPI). PPI can affect the quality of life for both men successfully treated as well as those who go on and eventually develop advanced prostate cancer. One of the more common, but last efforts [...]
Before I get into the meat of today’s post about enzalutamide, I want to briefly make some personal comments about my absence from this blog. As I had mentioned I have been diagnosed with a fifth primary cancer, appendiceal cancer. It is a rare cancer, which required my having to remove my appendix, a piece [...]
President Obama’s fiscal year 2016 budget eliminates all funding for the Centers for Disease Control prostate cancer program. Congress has the power to protect the CDC Prostate Cancer program. We ask for your advocacy to protect this life saving program. Please go to http://malecare.org/cdc There, you will find a sample letter, which you are welcome to copy whole or [...]
It was announced today that preliminary results from the Phase II STAND trial demonstrates continued and what is described as a robust immune response with Provenge (sipuleucel-T) that continues two years after completing treatment in men with biochemically-recurrent prostate cancer (BRPC). This finding, along with data from the ongoing Phase IV registry PROCEED trial, are [...]